What Your CEO is Reading: The Insulin Price Cap

On March 1, Eli Lilly announced they would cap patient out-of-pocket (OOP) costs for insulin at $35 per month at participating retail pharmacies. While this improves access to insulin for patients who may struggle to afford the drug, the manufacturer’s announcement presents other potentially significant implications for employers.